Evidence map›Paper›PMID 35059864›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.

Mashari Alzahrani, Carol Stober, Michelle Liu, Arif Awan, Terry L Ng, Gregory Pond, Bader Alshamsan, Lisa Vandermeer, Mark Clemons

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mashari AlzahraniDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, Canada.
Carol StoberCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Michelle LiuCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Arif AwanDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, Canada.
Terry L NgDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, Canada.
Gregory PondDepartment of Oncology, McMaster University, Hamilton, Canada.
Bader AlshamsanDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, Canada.
Lisa VandermeerCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Mark ClemonsDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, Canada. mclemons@toh.ca.ORCID http://orcid.org/0000-0002-0738-2713
Ottawa Hospital · CAUniversity of Ottawa · CAMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial evaluated SSEs in patients receiving BMAs at a single cancer center.

methodsData from patients with metastatic breast and castration-resistant prostate cancer (CRPC) were interrogated to evaluate the effects of longer-term use of BMAs on incidence, type, and risk factors for SSEs.

resultsOf 162 patients, 109 (67%) had breast cancer (BC) and 53 (33%) CRPC. Median age at diagnosis of bone metastases was 61.9 years (range 27.5-97.2) for BC patients and 72.1 (range 37.0-92.2) for CRPC patients. Median duration of BMA use was 2.3 years (range 0.1-9.9 years) for BC and 3.8 years (range 1.5-9.4) for CRPC patients. The initial BMAs in BC patients were pamidronate (46.8%), denosumab (31.2%), and zoledronate (22%). All CRPC patients received denosumab. During follow-up, 59% of BC and 75% of CRPC patients had at least one SSE. The number of patients experiencing ≥ 1 SSE per year was higher in the first year after bone metastasis diagnosis (63/162; 38.9%) compared with that in the second (26/149; 17.5%) and third years (30/123; 24.4%). Neither age, visceral disease, multiple bone metastases, nor biological markers for BC had a significant impact on time to first SSE.

conclusionsThe risk for SSEs was greatest in the first year after diagnosis of bone metastasis. Studies evaluating de-escalation and even stopping of BMAs with longer-term use may therefore be warranted.

Indexed as

Bone NeoplasmsProstatic Neoplasms, Castration-ResistantAdultAgedAged, 80 and overCastrationHumansMaleMiddle AgedRetrospective StudiesZoledronic AcidZoledronic AcidBone metastasesBreast cancerProstate cancerSkeletal-related events

Identifiers

PMID35059864
OpenAlexW4206248424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.